XELOX与FOLFOX6方案一线治疗晚期结直肠癌近期疗效及不良反应比较.docVIP

XELOX与FOLFOX6方案一线治疗晚期结直肠癌近期疗效及不良反应比较 　　摘要：目的：比较分析XELOX与FOLFOX6一线治疗晚期结直肠癌的近期疗效以及不良反应情况。方法：选取我院收治的40例晚期结直肠癌患者为研究对象，将其随机分为A组和B组，每组各20例，A组患者采用XELOX（卡培他滨联合奥沙利铂）方案治疗，B组患者采FOLFOX6（亚叶酸钙（CF）、5-氟尿嘧啶（5-FU）联合奥沙利铂）方案治疗，对比两组患者的疗效和不良反应。结果：A组患者治疗有效率为50.0%，B组为45.0%，两组差异不具显著性（P0.05）。A组患者中性粒细胞减少、神经毒性、血小板减少发生率明显低于B组（P0.05），而手足综合征的发生率则明显高于B组（P0.05）。结论：XELOX和FOLFOX6方案治疗晚期结直肠癌的近期疗效方面无显著差异，而前者比后者用药更为方便，且不良反应情况整体优于后者，有更高的临床应用价值。 　　关键词：晚期结直肠癌；卡培他滨；奥沙利铂； 　　Abstract ：objective： comparative analysis of XELOX and FOLFOX6 first-line treatment of advanced colorectal cancer in the near future curative effect and adverse reactions. Methods： 40 cases of patients with advanced colorectal cancer to select our hospital as the research object， its were randomly divided into group A and group B， 20 cases in each group， A group of patients using XELOX （capecitabine in combination with oxaliplatin into） solution treatment， the patients in group B FOLFOX6 （calcium leucovorin （CF）， 5 - fluorouracil （5 FU） in combination with oxaliplatin into） solution treatment， compared two groups of curative effect and adverse reaction of patients. Results： the patients of group A treatment effective rate of 50.0%， B group was 45.0%， has no significant difference in the two groups （P 0.05）. A group of patients with neutropenia， neurotoxicity， the incidence of thrombocytopenia was lower than that in group B （P 0.05）， while the incidence of hand， foot and syndrome is significantly higher than group B （P 0.05）. Conclusion： FOLFOX6 scheme and XELOX short-term curative effect on the treatment of advanced colorectal cancer has no significant difference， while the former drug use is more convenient than the latter， and adverse reaction conditions overall superior to the latter， has a higher clinical value. 　　Keywords ：the late colorectal cancer； Capecitabine. Oxaliplatin into； 结直肠癌是临床中常见的恶性肿瘤疾病，该病的早期诊断率较低[1]。据报道，有接近33%的患者在初诊时已有转移，而且即使可以进行手术治疗的患者，仍有50%的几率会因为转移或复发而进展为晚期癌症[2]。晚期结直肠癌主要采用化疗进行治疗，不同化疗方案的效果、不良反应发生率、生存率不同。为此，收集本院收4